Stocks

Brown-Forman B (BF.B) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Brown-Forman B (BF.B) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Aspen Group Inc. (ASPU) Report Negative Earnings Next Week? What You Should Know

Aspen Group Inc. (ASPU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intel (INTC) To Take Mobileye Public: What This Means For The Stock

After 3 years of significant underperformance and a seemingly endless flow of negative headlines, Intel final has some positive news for its patient shareholders

Daniel Laboe

Coal Prices Keep Rising: Can You Exploit Them?

Coal prices are soaring and are likely to continue that way in the near term. Does this mean you should invest in the segment?

Sejuti Banerjea

3 Reasons Growth Investors Will Love Liberty Broadband (LBRDK)

Liberty Broadband (LBRDK) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Tilly's (TLYS) Is a Great Growth Stock

Tilly's (TLYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why West Pharmaceutical (WST) Is a Great Growth Stock

West Pharmaceutical (WST) could produce exceptional returns because of its solid growth attributes.

Descartes Systems (DSGX) is an Incredible Growth Stock: 3 Reasons Why

Descartes Systems (DSGX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Forward Air (FWRD) is an Incredible Growth Stock: 3 Reasons Why

Forward Air (FWRD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

AbbVie's (ABBV) Rinvoq Meets Goals in Crohn's Disease Study

AbbVie's (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn's Disease.

Reasons to Bet on FactSet Research Systems (FDS) Stock Now

The recent acquisition of Cobalt Software is expected to enhance FactSet's data and workflow solutions through prudent investments and expand its private markets offering.

ACADIA's (ACAD) Rett Syndrome Candidate Meets Goal in Study

ACADIA's (ACAD) phase III study, evaluating the efficacy and safety of trofinetide in patients with Rett syndrome, meets co-primary endpoints. Shares rise.